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Summary. We have previously demonstrated that high 
doses of recombinant human granulocyte colony- 
stimulating factor (rhG-CSF) induce bone changes 
characterized by osteoclastic bone resorption and 
osteogenesis due to intramembranous ossification in rats. 
In this communication we examined the effects of a 
pretreatment with 3-amino-l-hydroxypropylidene-1,l- 
bisphosphonate (AHPrBP), which is a powerful inhibitor 
of osteoclastic bone resorption, on bone changes induced 
by rhG-CSF in order to investigate the relation between 
osteoclastic bone resorption and osteogenesis. AHPrBP 
(5 mg/kg/day) was subcutaneously given to 6-week-old 
rats for 2 days. From the following day of the final 
injection of AHPrBP, rats received a subcutaneous 
injection of rhG-CSF (1,000 pg/kg/day) for 14 days, and 
the femur and tibia were evaluated histopathologically. 
By the analysis of peripheral blood leukocyte counts, 
spleen weights and bone marrow findings, the 
pretreatment with AHPrBP had no effect on the 
activation of hematopoiesis related to the major 
pharmacological activity of rhG-CSF. In the rats treated 
with rhG-CSF alone, accelerated osteoclastic bone 
resorption and osteogenesis due to intramernbranous 
ossification were observed in the trabeculae of 
metaphyseal spongiosa. The accelerated osteoclastic 
bone resorption induced by rhG-CSF was suppressed by 
the pharmacological activity of AHPrBP. Furthermore, 
the osteogenesis induced by rhG-CSF was  also 
suppressed by AHPrBP. These results suggest that the 
osteogenesis induced by rhG-CSF is a sequential 
reaction of accelerated osteoclastic bone resorption, and 
moreover that the main action of rhG-CSF on bone is an 
acceleration of osteoclastic bone resorption. 
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Introduction 
A large number of studies have suggested that 
colony-stimulating factors (CSFs) regulate the 
proliferation and differentiation of hematopoietic 
progenitor cells and that granulocyte CSF (G-CSF) 
acts on the granulocyte lineage and enhances some 
functions of mature granulocytes (Demetri and Griffin, 
1991). 
Recently, accelerated osteoclastic bone resorption 
andtor increased in number of osteoclasts have been 
reported in rats (Keller and Smalling, 1993; Soshi et al., 
1996; Suzuki et al., 1997a-c) and mice (Lee et al., 1991) 
exogenously administered with recombinant human G- 
CSF (rhG-CSF), and in human G-CSF-transgenic mice 
(Takahashi et al., 1996). These observations suggest that 
G-CSF plays a role in the process not only of hemato- 
poiesis but also of bone modulation. Furthermore, Keller 
and Smalling (1993) and the authors (Suzuki et al., 
1997a-c) have demonstrated that osteogenesis due to 
intramembranous ossification was also observed in rats 
exogenously administered with rhG-CSF. In addition, we 
reported previously that bone resorption was observed in 
almost all lesions, and some of which accompanied 
osteogenesis. Lesions showing osteogenesis alone were 
observed in only a few areas (Suzuki et al., 1997b,c). 
This result suggests that the osteogenesis due to intra- 
membranous ossification might be a coupling 
phenomenon after bone resorption. However, the 
relation between bone resorption and osteogenesis in 
bone changes induced by rhG-CSF is still obscure, and 
the role of G-CSF in bone modulation is poorly 
understood. 
The present experiment was therefore undertaken to 
determine whether the rhG-CSF-induced osteogenesis is 
dependent upon bone resorption by testing the effects of 
bisphosphonate, which has a high affinity for hydroxy- 
apatite crystals and is a powerful inhibitor of osteoclastic 
bone resorption (Boonekamp et al., 1986; Fleisch, 1987; 
Lowik et al., 1988; Flanagan and Chambers, 1989), on 
the rhG-CSF-induced bone changes. 
Bone changes induced in rats by rhG-CSF 
Materials and methods 
Animals 
Twenty male Sprague-Dawley rats were purchased 
from Japan SLC Inc. (Shizuoka, Japan) and subjected to 
the experiments at the age of 6 weeks. The animals were 
housed in cages (51cage) in an animal room maintained 
at a temperature of 2322 "C, a relative humidity of 
55+10% and a 14-hour light and 10-hour dark cycle, and 
they were fed pelleted chow (MF; Oriental Yeast Co., 
Ltd., Tokyo) and tap water ad libitum. 
Injection of rhG-CSF and bisphosphonate 
Recombinant human G-CSF (250 pg/ml) produced 
by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan) was 
used for this study. Bisphosphonate (3-amino-l-  
hydroxypropylidene-1,l-bisphosphonate, AHPrBP) was 
purchased from Ciba-Geigy Pharmaceutical Co. (Basel, 
Switzerland), and was dissolved in saline to a final 
concentration of 1.25 mglml. 
AHPrBP was subcutaneously injected into rats (over 
the upper back) at the dose level of 5 mgkg once a day 
for 2 days. From the following day of the final injection 
of AHPrBP, rats received subcutaneous injection of rhG- 
CSF at the dose level of 1,000 pg/kg once a day for 14 
days. 
Study design 
The rats were divided into 4 groups of 5 animals 
each, receiving: 1) saline for 16 days (totally negative 
control), 2) rhG-CSF after 2-days saline treatment (rhG- 
CSF-treated group), 3) saline for 14 days after AHPrBP 
treatment (AHPrBP-treated group), and 4) rhG-CSF 
after AHPrBP treatment (rhG-CSF+AHPrBP-treated 
group). All animals were weighed on days 0 (first dosing 
day), 2, 5, 9, 12 and 16, and the doses of rhG-CSF and 
AHPrBP were weight-adjusted. During the injection 
period, clinical signs of all animals were observed every 
day. On the day following the final injection, all animals 
were sacrificed by exsanguination under ether  
anesthesia. Before necropsy, peripheral blood leukocyte 
(white blood cell (WBC)) counts were measured in 
blood samples obtained from the abdominal aorta using 
a multiparameter auto-cell counter (electrical resistance 
detection, 'CC-780; Toa Medical Electronic Co. Ltd., 
Hyogo, Japan). Furthermore, serum samples were 
obtained from the abdominal aorta, and calcium (Ca) 
and inorganic phosphorus (IP) were measured using the 
o-cresolphtalein complexon and modified Taussky 
method, respectively. 
Bone histopathology 
At necropsy, the femur (distal metaphysis), tibia 
(proximal metaphysis), and spleen were removed from 
each animal, and the spleen was weighed. The bones 
were fixed in 10% neutral-buffered formalin and 
embedded in paraffin after ethylenediaminetetraacetic 
acid (EDTA) decalcification. Longitudinal thin sections 
were made and stained with hematoxylin and eosin 
(HE). 
For enzyme histochemical study, the tibia (proximal 
metaphysis) was fixed in periodate-lysine-paraformalde- 
hyde fixative (containing 4% paraformaldehyde) 
(McLean and Nakane, 1974) overnight at 4 'C. The 
specimens were decalcified in EDTA-glycerol solution 
(Mori et al., 1988) for 5 weeks at -5 "C, and embedded 
in paraffin by AMeX methods (Sato et al., 1986). 
Sections of the specimens were deparaffinized in xylene 
and acetone, and enzyme histochemically stained. The 
tartrate-resistant acid phosphatase (TRAP) activity was 
detected according to the procedure using naphtol AS-B1 
phosphate (Sigma Chemical Co., St. Louis, MO) as 
substrate and hexazotized pararosaniline (Sigma 
Chemical Co.) as coupler, and the substrate solution was 
completed by adding 100 mM L(+)-tartaric acid (Barka 
and Anderson, 1962). 
Statistical analysis 
Group mean values and standard deviations were 
calculated for body weight, WBC counts, serum Ca, 
serum IP and spleen weight. These data were analyzed 
for statistical significance of any differences between the 
control group and each drug-treated group, using 
Student's or Welch's t-test at levels of 1 and 5%. 
Results 
Clinical signs and body weights 
No abnormal clinical signs were observed in any 
group. Figure 1 illustrates the body weights. The body 
weights of the rhG-CSF- and the AHPrBP-treated 
groups were judged not to be different from those of the 
control group. The  body weight at day 16  was 
significantly lower in the rhG-CSF+AHPrBP-treated 
group than in the control group. 
WBC counts, spleen weights and bone marrow findings 
Marked increase in WBC counts and prominent 
splenomegaly were observed in the rhG-CSF- and the 
rhG-CSF+AHPrBP-treated groups (Table 1). In addition, 
no significant difference was observed in the WBC 
counts and spleen weight between the rhG-CSF-treated 
and the rhG-CSF+AHPrBP-treated groups. In the bone 
marrow, an increase of granulopoietic cells was observed 
in the rhG-CSF- and the rhG-CSF+AHPrBP-treated 
groups, and marrow cavities were fully occupied by 
hematopoietic cells. 
Serum Ca and /P values 
No significant changes in serum Ca and IP levels 
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were observed in all groups (Table 1). 
Histopathological nature of bone changes 
The histopathological nature of bone changes is 
summarized in Table 2. 
In the rhG-CSF-treated group,  bone changes 
characterized by accelerated osteoclastic bone resorption 
and osteogenesis due to intramembranous ossification 
were observed in the metaphyseal spongiosa of femur 
and tibia (Figs. 2b, 3-5). The changes were distributed in 
the area from the secondary spongiosa to the interface of 
primary spongiosa and secondary spongiosa. In the 
spongy trabeculae, a large number of osteoclasts and 
bone resorption bays (Howship's lacunae) were observed 
on the bone surface (Fig. 3). The medullary cavity 
around or beside resorptive bones was replaced by 
mesenchymal tissues composed of various types of 
stromal cells. Numerous osteoclasts and round- to 
polygonal-shaped mononuclear cells showing TRAP 
activity (preosteoclast/osteoclast precursor) were also 
observed on the bone surface and in the mesenchymal 
tissues (Fig. 4). In addition to the aforementioned 
findings, newly formed bones showing irregular shape, 
and woven bone structures that had no spicules of 
calcified cartilage were observed in andtor near the areas 
replaced by mesenchymal tissues (Fig. 5). These bones 
were filled with osteoid osteocytes, and their surfaces 
were covered with mono- or multilayered formative 
osteoblasts. 
In the AHPrBP-treated group, the amount of 
trabeculae in the rnetaphysis was greatly increased over 
Table 1. Peripheral blood leukocyte counts, blood biochemical values, 
AHPrBP- rhG-CSF-iniection 
injection 
I ,  I , , ,  I I I I I I , , , , ,  
0 2 5 9 12 16 
Days of injection 
Flg. 1. Body weights of rats injected with saline (control; white circle), 
1,000 pg/kg of rhG-CSF (black circle), 5 mg/kg of AHPrBP (white 
square), and both 1,000 pg/kg of rhG-CSF and 5 mglkg of AHPrBP 
(black square). Each value represents the rnean2SD (n=5). 
*: Significantly different from the control (p<0.05). 
and spleen weight of rats injectedhith rhG-CSF and AHPrBP. 
GROUP WBC CA I P SPLEEN 
(xl  03/pl) (mgldl) (mgldl) (mg) 
Control 6.720.8 10.49?0.13 9.67a.52 694+114 
rhG-CSF 49.4?8.7* 10.29*0.37 9.32?1.00 2,121 +l 84* 
AHPrBP 6.921.2 10.44*0.49 8.58k0.72 605?51 
rhG-CSF + AHPrBP 60.9*14.9* 10.1 8t0.34 8.94t0.70 2,230+297* 
Each value represents the meankSD (n=5). *: significantly different from 
the control (p<0.01). 
controls, and the area of spongiosa extend further 
towards the diaphysial region (Fig. 2c). Spicules of 
calcified cartilage were observed in the middle of the 
trabeculae (Fig. 6a). On the trabecular bone surfaces, a 
large number of osteoclasts were observed (Fig. 6a, 7a), 
whereas ruffled border of osteoclasts and bone 
resorption bays on bone surface were not found. 
In the rhG-CSF+AHPrBP-treated group, histo- 
pathological findings of bone were the same as those of 
the AHPrBP-treated group (Fig. 2d, 6b, 7b). Namely, 
trabeculae with spicules of calcified cartilage were more 
numerous in the metaphysis, and extended further 
towards the diaphysial region. On the trabecular bone 
surfaces, a large number of osteoclasts without ruffled 
border were observed, and bone resorption bays were 
not found. 
Discussion 
Recently, we have demonstrated that bone changes 
characterized by accelerated osteoclastic bone resorption 
and osteogenesis due to intramembranous ossification 
were observed in rats administered with 100 and 1,000 
pglkgtday of rhG-CSF for 28 days (Suzuki et al., 
1997b). By the analysis of incidence and distribution of 
bone resorption and osteogenesis induced by rhG-CSF, it 
was suggested that osteogenesis might be a coupling 
phenomenon after bone resorption (Suzuki et al., 1997b). 
It has been established that bone resorption and osteo- 
genesis are sequential processes. Bone resorption occurs 
first, and osteogenesis occurs after bone resorption. 
These activities are coupling, such that under normal 
circumstances increased bone resorption is followed by 
increased osteogenesis,  and suppression of bone 
resorption suppresses osteogenesis (Jaworsk, 1984). In 
addition, suppression of bone resorption by calcitonin, 
estrogen, and bisphosphonates causes a decrease in 
osteogenesis, and increased bone resorption, as seen 
after ovariectomy, causes an increase in osteogenesis 
(Wronski et al., 1988a,b, 1991; Hayashi et al., 1989; 
Seedor et al. ,  1991;  Stein et al., 1991). I f  the 
osteogenesis induced by rhG-CSF is  coupled to 
increased bone resorption, osteogenesis will be 
suppressed by suppression of bone resorption. Thus, we 
examined the effects of pretreatrnent of AHPrBP on 
bone changes induced by rhG-CSF. 
Bone changes induced in rats by rhG-CSF 
In the present study, rhG-CSF was given to rats for logical activity of rhG-CSF (Demetri and Griffin, 1991; 
14 days at dose level of 1,000 pglkg. Marked increase in Keller and Smalling, 1993), were observed in the rhG- 
number of WBC counts, prominent splenomegaly with CSF- and rhG-CSF+AHPrBP-treated group. There were 
extensive extramedullary hematopoiesis (Keller and no differences in the aforementioned findings between 
Smalling, 1993) and granulocytic hypercellularity of the rhG-CSF-treated group and the rhG-CSF+AHPrBP- 
bone marrow, which are related to the major pharmaco- treated one. These results indicated that the pretreatment 
Table 2. Histopathological findings of bone in rats injected with rhG-CSF and AHPrBP 
FINDINGS CONTROL rhG-CSF AHPrBP rhG-CSF + AHPrBP 
Femur Tibia Femur Tibia Femur Tibia Femur Tibia 
rhG-CSF-related changes 
Accelerated osteoclastlc bone resorption 0* 0 4 4 0 0 0 0 
Osteogenesis due to intramembranous ossification 0 0 3 3 0 0 0 0 
AHPrBP-related change 
Increase in metaphyseal spongy trabeculae 0 0 0 0 5 5 5 5 
Each group is composed of 5 rats. *: number of rats with changes. 
Flg. 2. Femur sections of rats injected with saline (a; control), 1,000 pglkg of rhG-CSF m), 5 mglkg of AHPrBP (c), and both 1,000 pglkg of rhG-CSF 
and 5 mQ/kg of AHPrBP (d). b. Bone changes involving the replacement of medullary cavity by mesenchymal tissues are observed in the metaphysis. 
c and d. The amount of trabecular in the metaphysis is greatly increased. HE, X 40. 
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with AHPrBP did not affect the major pharmacological 
activity of rhG-CSF. 
In the AHPrBP-treated group, the amount of 
trabeculae in the metaphysis was greatly increased. The 
fact that spicules of calcified cartilage were observed in 
the trabeculae indicated that the trabeculae occupying 
the metaphysis were cartilage bone due to enchondral 
ossification from growth plate. On the bone surfaces, an 
increase in number of osteoclasts was observed, whereas 
ruffled border of osteoclasts and bone resorption bays on 
bone surface were not found. These findings suggested 
that osteoclastic bone resorption was suppressed, and 
then, unresorbed enchondral bone (also called cartilage 
bone) trabeculae occupied the metaphysis. Therefore, it 
was confirmed that AHPrBP exhibited its effect of 
resorption-suppression in this study. 
In the rhG-CSF-treated group, bone changes 
characterized by accelerated osteoclastic bone resorption 
and osteogenesis due to intramembranous ossification 
were observed. The histopathological nature of bone 
changes was similar to that in our previous studies 
(Suzuki et al., 1997b,c). In the rhG-CSF+AHPrBP- 
treated group, histopathological findings of bone were 
the same as those in the AHPrBP-treated group. The 
increase in number of osteoclasts was observed in the 
rhG-CSF- and rhG-CSF+AHPrBP-treated groups. It is 
known that, in growing rats treated with AHPrBP, the 
increase in number of osteoclasts is a secondary reaction 
occurring after the increase in amount of bone tissues 
due to suppressed osteoclastic bone resorption (Miller 
and Jee, 1975, 1977,  1979;  Reitsma et al., 1980; 
Flanagan and Chambers, 1989). It is considered that the 
increase in number of osteoclasts in the rhG- 
CSF+AHPrBP-treated group involved both the effect of 
rhG-CSF and the secondary reaction of AHPrBP- 
treatment. 
In the rhG-CSF+AHPrBP-treated group, the 
accelerated osteoclastic bone resorption induced by rhG- 
CSF was suppressed by the pharmacological activity of 
AHPrBP. Furthermore, the osteogenesis due to 
intramembranous ossification induced by rhG-CSF was 
also suppressed by pretreatment with AHPrBP. These 
results suggest that the osteogenesis induced by rhG- 
CSF  is dependent on the presence of a coupling 
mechanism, and moreover that the osteogenesis is a 
sequential reaction of accelerated osteoclastic bone 
resorption induced by rhG-CSF. The main action of rhG- 
CSF on bone, therefore, seems to be the acceleration of 
osteoclastic bone resorption. 
It has been established that osteoclasts are derived 
from hematopoietic stem cell population and that the 
CSFs, especially macrophage CSF, regulate the 
Fig. 3. Femur section of a rat injected with rhG-CSF. In the trabeculae, 
a large number of osteoclasts and resorptive bays (Howship's lacunae) 
are obsewed. HE, X 160 
Fig. 5. Femur section of a rat iniected with rhG-CSF. Irreqular-shaped 
Flg. 4. Tibia section of a rat injected with rhG-CSF. TRAP-positive woven bones are seen near the area replaced by mesenchymal tissues. 
osteoclasts and mononuclear cells are observed on the bone surface The bones are filled with osteoid osteocytes, and their surfaces are 
and in the mesenchymal tissues, X 125 covered with formative osteoblasts. HE, X 125 
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